Inhibrx Biosciences, Inc. (INBX) Earnings History
Net Loss10 years of earnings data (2016–2025) · Currently unprofitable on a TTM basis
Loading earnings history...
Inhibrx Biosciences, Inc. (INBX) Earnings Overview
As of June 30, 2026, Inhibrx Biosciences, Inc. (INBX) reported trailing twelve-month net income of -$130M, reflecting -107.8% year-over-year growth. The company earned $-8.35 per diluted share over the past four quarters, with a net profit margin of -10773.5%.
Looking at the long-term picture, INBX's historical earnings data spans multiple years. The company achieved its highest annual net income of $1.69B in fiscal 2024.
Inhibrx Biosciences, Inc. is currently reporting a net loss, though operating performance should be evaluated in the context of growth investments and industry dynamics View revenue history →
Compared to peers including IMVT (-$506M net income), ARQT (-$2M net income, -4.3% margin), KYMR (-$315M net income, -794.4% margin), INBX has comparable earnings metrics. Compare INBX vs IMVT →
INBX Earnings vs Peers
Earnings metrics vs comparable public companies
INBX Historical Earnings Data (2016–2025)
10 years| Fiscal Year | Net Income | YoY % | Operating Income | EPS (Diluted) | Net Margin | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | -$140M | -108.3% | -$135M | $-9.04 | -10773.5% | -10386.5% |
| 2024 | $1.69B | +799.2% | -$331M | $116.58 | 843786.0% | -165724.0% |
| 2023 | -$241M | -66.2% | -$219M | $-5.12 | -13408.9% | -12178.9% |
| 2022 | -$145M | -77.6% | -$129M | $-3.62 | -6625.3% | -5890.4% |
| 2021 | -$82M | -8.1% | -$77M | $-2.15 | -1147.6% | -1074.6% |
| 2020 | -$76M | -47.2% | -$67M | $-2.99 | -590.5% | -526.6% |
| 2019 | -$51M | -64.9% | -$44M | $-1.41 | -565.3% | -480.7% |
| 2018 | -$31M | -60.3% | -$30M | $-1.15 | -415.5% | -393.5% |
| 2017 | -$19M | -135.1% | -$20M | $-0.68 | -244.6% | -248.2% |
| 2016 | -$8M | - | -$12M | $-0.23 | -124.0% | -182.2% |
Download Data
Export INBX earnings history in CSV or JSON format
Free sign-in required to download data
Intrinsic Valuation
DCF models, multiple analysis, and analyst estimates.
Historical Returns
10+ years return with dividends reinvested.
DCA Calculator
See how regular investing compounds over time.
Peer Comparison
Compare growth, multiples, and margins vs sector.
INBX — Frequently Asked Questions
Quick answers to the most common questions about buying INBX stock.
What is INBX earnings per share (EPS)?
INBX trailing twelve-month (TTM) diluted EPS is $-8.35, reflecting -107.8% year-over-year growth. The 5-year EPS CAGR is N/A. Complete EPS history from 2016 to 2025 is available in the table on this page.
What is Inhibrx Biosciences, Inc.'s net income?
Inhibrx Biosciences, Inc. (INBX) trailing twelve-month net income is $-130M as of 2025. Earnings declined -107.8% year-over-year.
Is INBX profitable?
INBX is not currently profitable on a TTM basis, reporting a net loss of $-130M. Net margin is -10773.5%. Investors should monitor for a return to profitability.
What is INBX's earnings growth rate?
INBX compound annual EPS growth rates (CAGR): 1-Year: N/A, 3-Year: N/A, 5-Year: N/A, 10-Year: N/A. These figures measure the annualised rate of diluted EPS growth over each period, based on data from 2016 to 2025.
What are INBX's profit margins?
Inhibrx Biosciences, Inc. net profit margin is -10773.5%, operating margin is -10386.5%, and gross margin is -91.0%. Below-average margins reflect competitive or cost pressures. Return on Equity is -197.8%.
Is INBX growing earnings?
INBX earnings are declining — EPS fell -107.8% year-over-year. TTM net income dropped to $-130M. This contrasts with the 5-year CAGR of N/A.
What was INBX's best earnings year?
Inhibrx Biosciences, Inc.'s highest annual net income on record is $1.7B, achieved in fiscal year 2024. Earnings history on this page spans 2016 to 2025 and includes all annual and quarterly figures.
What were INBX's earnings last quarter?
INBX's most recent reported quarter was Q1 2026. Net income was $-33M with diluted EPS of $-2.15. For a full breakdown of all quarters, see the quarterly earnings table on this page.